{"id":7660,"date":"2005-01-29T15:33:19","date_gmt":"2005-01-29T14:33:19","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7660"},"modified":"2014-05-22T15:21:08","modified_gmt":"2014-05-22T15:21:08","slug":"atorvastatin-requires-dose-reduction-with-tipranavirr","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7660","title":{"rendered":"Atorvastatin requires dose reduction with tipranavir\/r"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Richard Hoetelmans and colleagues from Tibotec reported an interaction between the investigational protease inhibitor TMC-114 dosed at 300mg BID with 100mg ritonavir BID, and boosted and atorvastatin (AVS) in HIV-negative individuals.<\/strong><\/p>\n<p>Atorvastatin levels are increased by TPV\/r and a 10mg dose achieved around \u221215% exposure compared to 40mg AVS without TMC-114\/r.<\/p>\n<p>Similar reaction have been reported with other PIs and the recommendation for the study is to initiate AVS at 10mg and adjust based on clinical response.<\/p>\n<p>Reference:<\/p>\n<p>Hoetelmans R et al. The effect of TMC-114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics. 41st ICAAC, Washington, 2004. Abstract H-865.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Richard Hoetelmans and colleagues from Tibotec reported an interaction between the investigational protease inhibitor TMC-114 dosed at 300mg BID with 100mg ritonavir BID, and boosted and atorvastatin (AVS) in HIV-negative individuals. Atorvastatin levels are increased by &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[99],"class_list":["post-7660","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-icaac-44th-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7660"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7660\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}